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Abstract
There is a current biodefense interest in protection against Anthrax. Here we developed a new
generation of stable and effective anthrax vaccine. We studied the immune response elicited by
rPA delivered intranasally with a novel mucosal adjuvant, a mast cell activator Compound 48/80.
The vaccine formulation was prepared in a powder form by spray-freeze-drying (SFD) under
optimized conditions to produce particles with a target size of D50=25μm, suitable for delivery to
the rabbit nasal cavity. Physicochemical properties of the powder vaccines were characterized to
assess their delivery and storage potential. Structural stability of rPA was confirmed by CD and
ATR-FTIR, while functional stability of rPA and C48/80 was monitored by cell-based assays.
Animal study was performed using a unitdose powder device for direct nasal application. Results
showed that C48/80 provided effective mucosal adjuvant activity in rabbits. Freshly prepared SFD
powder vaccine formulations or powders stored for over two years at room temperature elicited
significantly elevated serum PA-specific and lethal toxin neutralization antibody titers that were
comparable to that induced by IM immunization with rPA. Nasal delivery of this vaccine
formulation may be a viable alternative to the currently licensed vaccine, or an attractive vaccine
platform for other mucosally transmitted diseases.
INTRODUCTION
Anthrax is a deadly disease caused by the rod-shaped, spore forming Gram-positive
bacterium, Bacillus anthracis. Anthrax infection occurs mainly in herbivores, with the spores
being present in different parts of infected animals as well as in soil. Human infections occur
through contact with skin, the lungs and GI tract. Upon entry into the human body, the
spores are taken up by macrophages and dendritic cells, and transported to lymph nodes
where they germinate to become the vegetative cells, followed by bacillar multiplication,
dissemination and toxin production. Eventually the bacteria can cause severe septicemia,
followed by shock and death. The vegetative cell of the bacteria is known to secrete three
proteins extracellularly, Protective antigen (PA), Lethal factor (LF) and edema factor (EF)
which are all responsible for the killing mechanism. While LF & EF have effects on cAMP
production and MAPK pathway, PA is essential to their cellular entry and endosome
escape 1.
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Most of the human cases in the US in recent decades have been sporadic and are limited to
natural causes 2. However, the 2001 anthrax attack through the US postal system shortly
after 911 was a reminder of the severity of this ancient disease. This marked the largest
outbreak of inhalational anthrax in US history. This intentional distribution of anthrax spores
emphasized the need for research on anthrax protection especially in the biodefense field.
The unique characteristics of Bacillus anthracis, in particular the stability, ease of dispersion
(aerosolization) of anthrax spores and the high morbidity and mortality rates have made the
aerosol spore form of the bacterium a leading bioweapon threat 3,4.
The inhaled form of anthrax is difficult to diagnose and can be fatal without prompt
antibiotic intervention. Prophylactic vaccination has become a critical measure for
protection of individuals at risk of exposure. In the U.S., the currently licensed anthrax
vaccine for human use is prepared from the sterile culture supernatant fraction of B.
anthracis which is adsorbed on aluminum hydroxide (AVA: BioThrax) for intramuscular
(IM) injection, while in the U.K. the supernatant is precipitated with aluminum phosphate
(AVP) for subcutaneous (SC) injection. These vaccines contain varying amounts of natural
PA with unknown amounts of LF and EF and rely on a complex six-dose primary
vaccination schedule which requires annual booster vaccination to maintain immunity 5. As
a result, unwanted side effects such as local injection-site reactions and systemic
reactogenicity have been reported after repeated vaccination. There is an increasing need for
more effective and tolerable anthrax vaccines able to elicit a rapid and durable response. A
new anthrax vaccine would be suitable for mass vaccination in response to an outbreak as
well as for vaccination in the developing world where anthrax epidemics are common.
Among many attempts to develop a second generation anthrax vaccine, purified
recombinant PA (rPA) has been selected as the antigen component. PA itself is not toxic,
and has been a major target for protective immunity against anthrax which is mainly
antibody-based. It is known that anti-PA antibody specific immunity not only has anti-spore
activity (to promote phagocytic uptake and suppress germination) 6, but also can prevent PA
from binding to its cellular receptor and subsequently binding lethal factor (LF) and edema
factor (EF) 7. Studies have shown that the rPA based-vaccine is capable of eliciting a
comparable functional antibody response (toxin-neutralizing titer) as the commercially
available vaccine AVA 8,9,10. Others have demonstrated administration of rPA can provide
complete protection against aerosol anthrax spore challenge in murine models as well as in
rabbits 9,10. Most encouragingly, rPA-based vaccines have been employed in clinical trials
to evaluate safety and efficacy 8,11,12. However, like the AVA vaccine, some results with
rPA-based vaccines indicate the requirement for an annual boost to ensure long-lasting
protection. Nevertheless, it is believed that rPA based vaccines with the addition of an
effective adjuvant warrant further investigation.
Vaccination via the nasal mucosa has been widely studied in animal models and is also in
clinical use 13,14. Recently, Flumist™ an intranasal (IN) influenza vaccine was approved by
FDA. The nasal mucosa is topically accessible and immunization via the nasal route may be
suitable for mass vaccination. In addition to systemic immunity, mucosal immunity can be
elicited 9,15-19 through nasal associated lymphoid tissue (NALT) where large amount of
local lymphocytes are present. Vaccination at the mucosal sites where the pathogens usually
initiate infection can be more efficacious than immunization by injection, since the pathogen
may be neutralized at the mucosal surface before having any systemic effect.
It is known that a successful mucosal vaccine requires an effective mucosal adjuvant. In
nasal vaccination formulations, the mucosal adjuvant enhances the antigen-specific mucosal
immune response and may result in a dose-sparing effect. Although, cholera toxin (CT) and
CpG are potent mucosal adjuvants in animal models 10,20-22 , concerns exist over the safety
Wang et al. Page 2













of CT used in human 23 and the possibility of eliciting an immune response to CpG
oligonucleotide after multiple boosting. Most recently, supported by the recognition of mast
cell’s immunomodulatory role in adaptive immune response 24-26, mast cell activators such
as Compound 48/80 have been studied as a new class of vaccine adjuvants and appear to be
highly effective and well-tolerated after nasal administration in mice and rabbits 27,28. It is
proposed in this current study that Compound 48/80 will be an effective adjuvant for nasal
vaccination when using a dry powder vaccine formulation containing rPA in a large animal
model, the rabbit.
Intranasal delivery of vaccines has typically been achieved using liquid formulations, which
requires a cold-chain for storage and transport to maintain vaccinepotency. There is a
growing interest in powder formulations of vaccines, which offers the potential to eliminate
preservatives and the cold-chain requirement for shipping and storage while maintaining
long term stability for room temperature storage and shipping 13,29-32. Spray-Freeze-Drying
(SFD) is a newly developed lab-scale process for dry powder preparation which is an
improvement of conventional spray drying and freeze drying in terms of protein structure
and activity preservation. Ge Jiang et al have demonstrated the preparation of a stable dry
powder formulation for anthrax vaccine by SFD, where trehalose was added as a bulking
agent and cryoprotectant 33. Trehalose is known for its ability to stabilize proteins under
temperature and drying induced stress conditions. Furthermore, Garmise et al. has
demonstrated that SFD process can be carried out under controlled conditions to produce
particles in the desired size ranges suitable for direct nasal vaccine delivery without further
size reduction 30. In the present study, we prepared rPA with the novel adjuvant C48/80 and
trehalose into a simple three component SFD dry powder formulation suitable for direct
nasal application. Physical properties of the powder formulation were characterized and the
biophysical stability of rPA was closely monitored. In addition, functional stability of rPA
and C48/80 were examined by in-vitro cell based assays following preparation and storage.
Finally, the in vivo immunogenicity of the powder formulation was evaluated with rabbit
nasal vaccination using a unitdose powder device (UnitDose, Aptargroup Inc. (formerly
Pfeiffer GmbH), IL, USA). This is the first report of compound 48/80 being used as a
vaccine adjuvant in a dry powder formulation for intranasal vaccination.
MATERIALS AND METHODS
Materials
Anthrax recombinant protective antigen (rPA) and recombinant lethal factor (rLF) was
obtained from List Biological Laboratories, Inc. (Campbell, CA). C48/80 and trehalose were
purchased from Sigma-Aldrich (St. Louis).
Experimental Methods
Powder preparation by Spray-Freeze-Drying—Aqueous solutions containing one or
more components of antigen, adjuvant and trehalose were prepared with an overall solute
concentration of 10% w/v, which were passed through a two-fluid pneumatic spray nozzle
(7mm diameter, Buchi Spray-Dryer B-191, Flawil, Switzerland) with a liquid feed rate of 10
ml/min. The typical batch size is 1-5 g of total powder in 10 - 50ml of aqueous solution.
Nitrogen gas with a flow rate of 500L/min and a fixed back pressure of 3 bar was used to
force the liquid into small droplets, which were collected in a stainless steel vessel
containing liquid nitrogen. Upon evaporation of liquid nitrogen in a −80°C freezer, the
frozen droplets were transferred to a pre-chilled jar and lyophilized for 72 hours with a
manifold temperature of −55°C and a vacuum pressure of 20 mTorr (Kinetics Flexi-Dry,
Kinetics Thermal Systems, Stone Ridge, NY).
Wang et al. Page 3













Particle Morphology and Size Determination—The morphology and shape of the
SFD powders were examined by Hitachi S-4700 Cold Cathode Field Emission Scanning
Electron Microscope. Samples were loaded on SEM pin stubs with double-sided adhesive
carbon conductive tab by dipping into dry powder stock, and sputter coated with Pd/Au with
a thickness of 3 nm.
Particle size analysis by laser diffraction was performed using particle-in-liquid (pil) mode
on Malvern 2600c (Malvern Instruments, Worcestershire, UK) with 100mm focal lens. A
small amount of powder from each formulation was suspended in a 1% Span 80 in light
mineral oil and sonicated for 10 seconds, which were added to a stirred sample cell (~15ml)
until idea sample concentration was reached (obscuration level of 20-30%). Volume median
diameter and span were measured.
Differential scanning calorimetry (DSC)—DSC (Perkin Elmer DSC 6, Wellesley,
MA) was performed on powder samples. Known quantities of the powders were loaded in
aluminum pans and differences in heat flow were measured against an empty reference pan.
Analysis was performed with a ramp rate of 10°C/min.
Moisture Analysis—Coulometric Karl-Fischer titration (Model 270, Denver Instrument,
Denver, CO.) was used to determine the moisture contents of the SFD powders.
Approximately 20-25 mg of powder was added to the reaction cell directly.
Circular Dichroism (CD)—Far-UV CD spectra (190nm-260nm) were recorded at 25°C
with an Applied Photophysics Pi-Star 180 circular dichroism spectrapolarimeter. Spectra
were recorded in 0.5nm steps and averaged over 1.25s. All measurements were carried out
in a 1-mm quartz cuvette. The powder vaccine formulation (SFD rPA formulation-2) was
reconstituted with deionized water, and was concentrated by centrifugation filter using a
Milllipore Centricon centrifugal filter device with an Ultracel® YM regenerated cellulose
membrane with a molecular weight cut-off of 30KDa (15°C, 5000 × g, 30min), while
removing interference from the adjuvant C48/80 at the same time. Protein retentate was then
recovered in 10mM phosphate buffer by reverse spinning at 1000 × g for 3 mins. Final
protein concentration for CD analysis is about 0.2 mg/ml. A blank spectrum with buffer only
was subtracted. Molar ellipticity [θ] in the units of deg.cm2.dmol−1 is calculated based on
the equation: [θ] = θ / (10 × C × l), where θ is the millidegree obtained from instrument, C
is the molar concentration of the protein and l = 0.1cm is the path length of the cuvette.
Attenuated Total Reflectance (ATR)-FTIR—FT-IR measurements were conducted
(FTIR-8400s, Shimadzu Corporation) in combination with attenuated total reflectance by
MIRacle™ ATR accessory equipped with ZnSe crystal (PIKE technologies). SFD rPA
formulation-2 was reconstituted and filtered through a Centricon® centrifulgal filter device
with Ultracel® YM-30 membrane, the protein component was recovered in 10mM sodium
phosphate buffer and loaded onto the crystal surface for direct measurements (scan range
1000cm−1-2000cm−1, 120scans, resolution 4cm−1). Buffer spectrum was subtracted from the
sample spectrum using IRsolution software. Each spectrum was minimum-maximum
normalized and the 2nd derivative was taken followed by curve smoothing (Savitzky-Golay
method).
SDS-PAGE & Native PAGE—SDS-PAGE was performed with a precast NuPAGE
4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA). Powder samples (reconstituted in deionized
water) and standards ~10μg per band were mixed with NuPage LDS sample buffer (Novex)
with addition of 5% (v/v) 2-Mercaptoethanol. Samples were incubated at 70°C for 10mins.
Electrophoresis was performed with NuPAGE MOPS SDS running buffer (Invitrogen) at
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constant voltage of 200V for 50min. The resulted gel was stained with GelCode Blue Stain
Reagent(Pierce Biotechnology, Rockford IL) and destained with distilled water.
Native-PAGE—A precast Native-PAGE™ Novex® 3-12% Bis-Tris Gel (Invitrogen) was
used to perform native electrophoresis. Powder samples (reconstituted in deionzed water)
~10μg per band was mixed with NativePage™ sample buffer and kept on ice prior to
loading. NativeMark™ Unstained protein standard was used as molecular weight reference.
Eletrophoresis was performed with NativePAGE™ anode and cathode buffer with cathode
additive (light blue) at constant voltage of 150V for 90min. Gel was stained with Colloidal
Blue Staining Kit (Invitrogen) after separation and destained with distilled water.
In-vitro Stability of Antigen and Adjuvant
Macrophage Toxicity Assay
Mouse macrophages are sensitive to LeTx(the combination of PA and LF )-induced
necrosis.. Here, rLF was added to the reconstituted powder formulation and the activity/
stability of rPA was evaluated by measuring the PA dependent toxicity of rLF using mouse
macrophage J774A.1 cells (ATCC, Manassas, VA). J774A.1 cells (6 ×104 cells/well) in
100μl Dulbecco’s Modified Eagles Medium (DMEM) phenol-red free with 10% fetal
bovine serum, 4.5 g/L Glucose and 2mM L-glutamine were seeded in a flat-bottom 96-well
microtiter plates and incubated for 24h at 37°C for cells to adhere at the bottom. rLF was
added to the reconstituted powder formulation and control rPA in a 1:1 ratio with a final
starting concentration of 1.5 μg/mL, followed by 2 fold serial dilution across the plate. After
incubation at 37°C for one hour, 100μl of the rPA/rLF mixture was transferred to the plate
containing the macrophage cells with media removed. The rPA/rLF mixture was incubated
with cells for 4 hours, 20μl of CellTiter 96 Aqueous One solution (Promega, Madison, WI)
was added and incubated for another 2 hrs before measuring the absorbance at 490 nm for
cell viability.
β-Hexoaminidase Release for Mast Cell Degranulation
Mast cell degranulation activity of the adjuvant was examined by measuring the release of a
granule marker, β-hexoaminidase 34. MC/9 cells (ATCC, Manassas, VA) were washed and
plated in Tyrode’s buffer (135 mM NaCl, 5mM KCl, 1.8mM CaCl2, 1mM MgCl2, 5.6 mM
glucose, 1mg/mL bovine serum albumin, and 20mM Hepes, pH 7.4) at concentration of 2
×105 cells/well. Cells were spun down, and media was removed. Powder formulations
reconstituted in Tyrode’s buffer with desired concentration of the stimulants were added to
the plate, and incubated at 37°C for 1.5 hour. β-Hexoaminidase substrate, p-Nitrophenyl-N-
acetyl-β-D-glucosainide (NAG, Sigma-Aldrich) 3.4 mg/mL was prepared in 0.1M citrate
buffer (pH 4.5). After the incubation, 30μl of the supernatant were taken from the mixture
and added to 10μl NAG in a separate plate which was further incubated for 1 hour. The
reaction was then stopped with 100μl sodium carbonate buffer (0.1M, pH 10), and
absorbance at 405nm was recorded. 0.1% Triton prepared in Tyrode’s buffer was used as
positive control. Percent degranulation was calculated using the following formula ((Test–
Media only) / (Triton–Media only)) × 100.
Storage Stability Studies of Anthrax Vaccine Formulations—The anthrax vaccine
formulations were aliquotted into 2mL micro-centrifuge tubes (Fisherbrand). Each tube
contained about 40-50 mg of SFD powder formulation, which was stored at 23°C, 40°C with
different humidity levels (55% RH maintained with saturated sodium bromide solution or
75% RH with saturated sodium chloride solution). After storage powder samples were
reconstituted in about 300-400μL of water for macrophage toxicity assay. Liquid
formulation containing rPA (125 μg/mL), C48/80 (100 μg/mL) and Trehalose (123 mg/mL)
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in sterile water were also prepared, 320μl of which were aliquotted into 2mL micro-
centrifuge tubes and stored at 4°C, 25°C and 40°C for in-vitro stability analysis.
Animal Study—Female New Zealand White rabbits ~2.5-3kg (Robinson Services,
Mocksville, NC) were cared and used under conditions approved by Duke University’s
Institutional Animal Care and Use Committee. Rabbits (4 rabbits/group) were anesthetized
with acepromazine/butorphanol (1mg/kg each) prior to intranasal immunization. Rabbits
were immunized three times on days 0, 21, and 42. Liquid formulations of rPA (30μg) with
or without C48/80 (120μg) in 200μl PBS (100μl each nostril) were delivered intranasally to
rabbits using a laboratory pipette or via IM injection. Powder vaccines of the same antigen
and adjuvant dose (30μg rPA, 120μg C48/80 in 15mgs of powder) were delivered using a
unitdose powder human device fitted with a tip (modified from P10000 pipette tip, with tip
diameter of 2.33mm) for smaller openings of rabbit nasal cavity (6-9mg per nostril). Rabbits
receiving liquid formulations were held on their back for 30s after nasal immunization
before returning to their cage, whereas rabbits were immediate turned over after receiving
nasal powder vaccination with Unitdose device. Blood samples were taken via marginal ear
veins on days 7, 35, and 56 for ELISA and toxin neutralization analysis.
ELISA—A fluorescent ELISA was used to measure serum anti-PA immunoglobulin G
(IgG) endpoint titers after each immunization. PA was coated onto black 384-well plates
(Nuncbrand) at a final concentration of 2 μg/mL in carbonate-bicarbonate buffer (CBC).
After incubation overnight at 4°C, Nonfat dry milk (3% w/v) in CBC buffer with Kathon
(0.1% v/v) was added and incubated for at least 2 h. to block the non-specific binding sites.
Plates were washed four times with ELISA wash buffer (0.1% kathon and 0.05% Tween20
in PBS) and diluted serum samples (1:32) were plated in complete sample diluents (1% w/v
bovine serum albumin, 1% w/v non-fat dry milk, 5% normal goat serum, 0.05% Tween20,
0.1% Kathon in PBS) for overnight incubation at 4°C. Plates were washed with ELISA wash
buffer and 20 antibody (goat anti-rabbit IgG, alkaline phosphatase conjugated, Southern
Biotech) was added with 1:5000 dilution in secondary antibody diluent (0.5% w/v bovine
serum albumin, 5% v/v normal goat serum, 0.05% v/v Tween20 and 0.1% v/v Kathon) and
incubated for at least 2 h at room temperature. Plates were washed with ELISA wash buffer
and 15 μl AttoPhos substrate (Promega) was added to each well and incubated for 15 min
before reading at 440nm(excitation)/560nm (emission). The endpoint titer corresponds to the
last serum sample dilution that gives a fluorescence value at least 3-fold higher than the
value of the corresponding naive sample at the same dilution. The log2 endpoint titers were
used for statistical analysis. Samples with no detectable anti-PA IgG titers were assigned a
value of 1 for statistical analysis.
Anthrax lethal toxin neutralization assay
Mouse macrophages are sensitive to LeTx(the combination of PA and LF )-induced
necrosis. An in vitro lethal toxin (LeTx) neutralization assay using J774A.1 mouse
macrophage cells was performed to determine the functional titer of the anti-PA antibody
present in rabbit serum. The details of the assay were reported previously 35. Briefly, rabbit
sera were incubated with PA for 1 hr at 37°C to allow neutralization to occur, followed by
incubation with added LF at room temperature for 1 hr. The serum-PA/LF mixture was then
added to the plate containing macrophage cells. The starting serum dilution on the final plate
is 1:128 or 1:27 with a final concentration of 0.1875 μg of LeTx (rPA+rLF) per ml. Percent
neutralization was calculated based on (sample OD value – LeTx standard OD value)/(cells
only OD value-LeTx standard OD value) 100. The percent neutralization was plotted vs
serum log2 dilutions and fitted with a second order polynomial curve. The serum dilution
able to neutralize 50% of LeTx (NT50) was calculated. Serum samples that had no
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detectable lethal toxin neutralization activity were assigned a log2 value of 1 for statistical
analysis.
RESULTS AND DISCUSSION
Physicochemical properties of SFD powders
Different SFD powder formulations were prepared, including SFD powder prepared with
trehalose alone, SFD C48/80 trehalose powder containing 12 μg of C48/80 per mg of
trehalose, SFD rPA formulation-1 containing 0.67 μg of rPA plus 10 ug of C48/80 per mg
of trehalose, and SFD rPA formulation-2 containing 2 μg of rPA plus 8 μg of C48/80 per
mg of trehalose. The amount and ratio of rPA and compound 48/80 in the SFD powder
formulations were adopted from liquid formulations optimized in the Staats lab.
Scanning electron micrographs (Figure 1) show that the particles prepared by SFD were
spherical and very porous, which is consistent with their relatively low tapped density
(Table 2). Low and high magnification of SFD trehalose formulation (Figure 1-A, B)
demonstrated primary particles with sizes consistent with LD measurements. SEM image of
C48/80 (Figure 1-C) showed spherical particle appears to have smaller pores and more
materials inside. The addition of protein to the formulation has yielded particles with hollow
porous structure as shown in image D and E. It seems that the particle backbone structure
becomes fragile as additional protein content is introduced to the trehalose bulk.
The volume median diameter of the SFD particles prepared from trehalose alone and protein
containing trehalose formulations were very close to the target size D50=25μm (Table 2)
when prepared under controlled SFD process optimized with trehalose alone. However, for
SFD powders prepared with just C48/80 and Trehalose, the overall particle size was
significantly smaller than those measured of SFD trehalose powder in terms of D10, D50 and
D90 (P < 0.05). Nevertheless, SFD formulations prepared with both adjuvant C48/80 and
antigen rPA had a similar D50 compared to SFD formulation made of pure trehalose.
Particle size distribution of these SFD particles appear to be bimodal or multimodal (Figure
2).
Powder flow properties influence the aerosol delivery efficiency of powder products. In the
current project, a simple CCI index based on powder bulk and tapped densities was used to
evaluate powder flow property. The bulk (0.05-0.16 g/ml) and tapped (0.08-0.24 g/ml)
densities of the SFD powders were significantly lower than bulk trehalose (~0.5 and 0.6 g/
ml). The bulk and tap densities of the SFD formulation-2 were similar to SFD trehalose
(Table 2). The SFD C48/80 particles have larger bulk and tap densities (0.16 and 0.24 g/m,
respectively) than other SFD formulations listed in the table. This observation is consistent
with reduction in particle size measured by SEM analysis and LD, suggesting the particles
are no longer maintaining bulk properties of SFD trehalose which could be a result of
introducing excess hydrophobic content to the trehalose formulation. The CCI indices for all
SFD powders were high (between 32-38%), suggesting the powders are easily compressible,
and indicating large cohesive forces acting on the SFD powders. This can be attributed to
the large porous structure of the SFD particle, the brittleness of the structure. The ambient
moisture levels during the experiment could influence the cohesive forces between the
particles due to the moisture sensitive nature of SFD trehalose. As mentioned in the
introduction, a free-flowing powder has a CCI less than ~20% to 21%. None of the SFD
powders would be considered free flowing based on their CCI index.
However, the flow property of the SFD powders as determined by CCI index did not seem
to dictate the performance of the final product. The powder device was able to deliver
almost all of SFD powders packed (loading amount 6-9mg). When the device was fitted
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with an extra tip for nasal delivery to rabbits, the emitted dose for SFD powders decreased
slightly with overall efficiency to be over 98% (Table 3). Aerosols delivered from the device
showed similar particle size distribution with powders measured in oil suspension (Figure
3). The overall volume diameters of emitted powders appear to be very close to SFD
powders measured by PIL. The volume median diameters observed were larger for powder
aerosols in PIA measurements, which may be explained by a modest aggregation
phenomenon. Nevertheless, these results indicate that SFD powders tested showed good
dispersion properties and delivery efficiency (complete dispersion) with the Unitdose
powder device.
Thermal properties and moisture content
The moisture content of the SFD powders was around 2-5% (Table 1) following
lyophilization and storage at room temperature with desiccant. To determine whether the
formulation components and the residual water content would affect the Tg of amorphous
trehalose, which, might subsequently, influence the optimum storage temperature, DSC
scans of SFD powders were performed at 10°C/min (Figure 4). Typical glass transition
peaks for SFD trehalose, SFD rPA-1 and SFD rPA-2 formulations were not detected in the
initial scan due to interference from other thermal transitions that occur at the same
temperature range, namely the preceding broad dehydration process, and the onset of an
accompanying relaxation endotherm at Tg (also called enthalpic recovery) 36. Since these
formulations were handled under ambient conditions during the one year storage before
DSC measurements, it is likely that residual water content in these powders acted as a
plasticizer and introduced increased molecular mobility of the amorphous trehalose matrix
which lead to structural relaxation. This enthalpic recovery was found overlapping the glass
transition peak, which prevented identification of the Tg in the first scan. Nevertheless, after
subjecting the sample to a heat-cool cycle, the second DSC scan showed fully resolved glass
transition, with a Tg of 106°C (see Figure 4 insert), which is consistent with literature
reports (106-120°C) 30,37,38. DSC results demonstrated that the addition of vaccine
components and the presences of residual water content did not change the matrix Tg
substantially, and these formulations may be stored at room temperature.
Structural stability and integrity of rPA
CD measures the protein secondary structure in the far-UV region. It is important to remove
any interference due to the buffer or any other component in the sample solution that has
high UV absorption that could mask the CD signal at lower wavelength. In the present
study, the reconstituted SFD rPA formulation-2 was subjected to ultrafiltration to eliminate
the UV absorbing C48/80 prior to CD analysis. Figure 5 shows the molar ellipticity of rPA
at the Far-UV region. The CD spectrum of rPA in the SFD formulation appears to be very
close to the unprocessed rPA protein. Both CD spectra display a broad negative absorption
with a single dominating minima at around 208nm, suggesting a mixture of α-helical and β-
sheet component, which is comparable to CD spectra of PA reported previously in the
literature 33. The positive α-helical signal near 195 nm (π0→π*) was not observed, which
may be due to interaction from certain aromatic amino acid side chain in PA 39.
ATR-FTIR experiments were carried out to confirm the result from CD experiments. Figure
6 shows the second derivative spectra of the two samples in the Amide I region
(1600-1700cm−1), which indicates similarity of the peak shape, position and intensity.
Different components of the secondary structure can be assigned according to the
literature 40. One major band at 1652 cm−1 has been assigned to α–helical component of the
structure. Several other band components at 1680cm−1, 1634cm−1 and 1618cm−1 are
attributable to formation of β-sheet in the protein structure. Finally, the small band
component at 1670 cm−1 is indicative of turn structure. These secondary structure
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components seems to correspond to the structure element of PA as reported in protein data
bank (PDB: 1ACC).
Both CD and FTIR spectroscopy confirmed the structural stability of PA in the SFD
formulation. The integrity of the protein was further examined by gel electrophoresis (Figure
7). SDS-PAGE (left image) under reducing conditions shows that powders stored for 1.5
years (lane 2) and freshly prepared powders (lane 3), have similar migration patterns to
unprocessed rPA control, which means the rPA is maintaining its molecular size and
integrity. This result is also true for samples prepared and analyzed under non-reducing and
native conditions, as shown in the right image. This result indicates the absence of antigen
aggregation due to oxidation.
Functional stability of rPA and compound 48/80
The biological functions of the adjuvant and antigen may be employed to examine their
functional stability in-vitro with cell-based assays. Compound 48/80 is a polymer prepared
from a condensation reaction of N-methyl-p-methoxyphenethylamine with formaldehyde 41.
A mixture of oligomers is thought to be formed, from trimer to octamer, with hexamer being
the most potent 42,43. It has been studied since the 1950’s as a potent mast cell activator that
promotes release of histamine44,45. Here the functional stability of C48/80 was examined by
mast cell degranulation assay. SFD rPA formulation-2 (stored at room temperature over
dessicant for 1.5 years) showed comparable mast cell degranulation activity with respect to
control C48/80 at different concentration dilutions Figure 8. Slight variability in the
degranulation activity among different formulation groups might be explained by the
difference in polymer distribution between batches of commercially available C48/80 42,46.
This result demonstrates functional stability of C48/80 after SFD process and upon 1.5 years
of storage.
In addition, the functional stability of rPA was assessed using a macrophage toxicity assay.
A 1:1 ratio of LF was added to reconstituted SFD formulations, where the cellular toxicity
of LeTx to macrophage cells was an indirect measurement for PA functionality since the
killing mechanism of LF can only occur with the assistance of functional PA for its cell
entry and endosomal escape 47. Figure 9 shows the cell viability across the PA/LF
concentration dilutions. Low optical density corresponds with few viable cells which, in turn
indicates PA is still active. The toxicity profile across PA/LF dilutions of LF+SFD rPA
formulation-2 prepared two years previously with room temperature storage over desiccant
and freshly prepared SFD rPA formulation-2+LF are very close to unprocessed control rPA
+rLF. When percent activity were calculated based on the log dilution level that can cause
50% cell death, the rPA within SFD rPA formulation-2 powder (2 yrs) and freshly prepared
SFD powders had a relative activity of 96% and 94%, respectively, compared to the
standard. Whereas, when LF was added alone, high optical density are observed across its
concentration dilutions, suggesting LF itself exerts no cellular toxicity to the macrophages.
In addition, when trehalose was added to the PA/LF standard, the relative PA activity
(104%) was also comparable to the PA/LF standard alone, suggesting trehalose did not
affect the in-vitro function of rPA+LF. This macrophage toxicity assay was a useful tool to
monitor the functional stability of PA after formulation, manufacturing process and storage.
Storage stability of powder formulations
SFD trehalose powder formulation appears to be highly moisture sensitive. Rapid moisture
sorption can reduce powder flowability, lead to powder collapse and dose delivery failure.
To gain a better understanding of the effect of moisture uptake on the stability of antigen,
and to identify an optimum storage condition for both the powder and liquid formulations,
liquid and powder formulations containing rPA, C48/80 and trehalose were prepared and
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stored under different temperature and different humidity levels (−80°C control, 4°C/liquid
only, 25°C/with desiccant, 25°C/ambient RH (~30-40% RH), 25°C/55% RH, 40°C/75%RH)
with either closed or open top vials. Instead of measuring physicochemical stability of rPA,
the storage stability of each formulation was estimated by rPA functional activity based on
macrophage toxicity assay.
Results (Figure 10-A) of SFD powder vaccine formulations stored at different conditions
show that the rate of rPA degradation increases as humidity level increases for storing SFD
powder formulations. SFD powder formulations stored with desiccant were the most stable
in terms of PA functional activity preservation (Figure 10-A, C). For SFD powders stored at
25°C at ambient humidity levels (~ 30-40% RH), initial fast degradation was observed
during the first week, then a steady PA activity level was reached . This might be due to an
initial recrystallization process that prevented further moisture uptake to the crystal core
which leads to a possible stabilizing effect, as indicated by DSC examination of SFD
powder vaccines stored under different conditions (data not shown). SFD powders stored in
a regular screw top plastic vial did not prevent moisture uptake and appeared to have a
similar degradation profile as powders stored in an open top vial. SFD powders stored at
55% RH were more susceptible to degradation. The rate was faster and similar to liquid
formulations stored at room 25°C (Figure 10-C).
The rate of degradation of the liquid formulation increased as temperature was elevated
(Figure 10-B). For liquid formulations stored at 40°C, PA activity was lost completely
within 1 day (Figure 10-B, D). However, the SFD powder formulation stored at the same
temperature and 75% RH level extended the PA activity for a longer period compared to
liquid formulations. Furthermore, when SFD powder formulation was stored over desiccant
at 40°C, 80% of the PA activity remained after two weeks (Figure 10-D).
Results from the previous function stability study showed that the SFD powder vaccine
formulations were stable upon 2 years of storage at room temperature (Figure 9). However,
the formulation was susceptible to degradation even at ambient humidity levels.
Consequently, SFD powders should be either stored using special sealed device or stored
with desiccant to limit moisture uptake. The upper limit of storage temperature can be
increased to 40°C for up to two weeks as long as the SFD has limited exposure to moisture,
which allows temperature fluctuation during storage and shipping.
Powder vaccine immunogenicity study in rabbits
Rabbit nasal SFD powder vaccination using Unitdose powder device—SFD
vaccine formulation prepared with trehalose appeared to be moisture sensitive and required
an appropriate device to prevent moisture uptake and ensure efficient and consistent delivery
of the powder dose. An animal study was carried out to further examine the in-vivo
immunogenicity of the SFD powder vaccine formulations using the Unitdose powder device
(Table 4). Two SFD powder formulations containing rPA + C48/80 were prepared with
trehalose under the same optimized SFD process, and had been stored in a dessicator for
either 2.5 years or 3 months before packing into the Unitpowder device (packing condition:
RT, RH level under 40%). SFD powder loaded devices were stored in a ziploc-type bag with
dessicant for 2-4 months before final testing in animal study.
Rabbits were immunized on days 0, 21 and 42 (see Materials and Methods). After the initial
immunization, no detectable serum anti-PA IgG was observed in rabbits vaccinated with
liquid formulation. However, rabbits in the two IN powder groups and IM liquid control
group showed 50% and 75% seropositive response, respectively, as determined by ELISA
analysis of serum collected on day 7 (Figure 11-A). Although there was no statistical
difference inthe anti-PA IgG titers between the any of the three seropositive groups was
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noted,our data demonstrates that a single nasal dose of powder vaccine was similar to liquid
IM immunization for eliciting an early vaccine-specific IgG titer, whereas nasal vaccination
with the liquid formulations failed to induce measurable serum antibody responses after the
first immunization. The fact that the powder vaccine formulation was able to induce
measurable immune responses after only one immunization suggests that powder nasal
vaccines are superior to liquid nasal vaccines and comparable to IM immunization for rapid
induction of vaccine-specific antibody response. This property of powder nasal vaccine may
be especially valuable if used in the event of emergency.
Following the second immunization, a substantial increase in IgG titers (on day 35) was
observed for all groups of rabbits (Figure 11-B) with the lowest being the group vaccinated
with liquid rPA lone which had a geometric mean anti-PA IgG titer of 1:92,682. All
adjuvanted groups including nasal liquid, nasal powder and IM liquid group had serum anti-
rPA GMT that were significantly greater than in rabbits immunized with rPA alone, with
titers in the range of 1:107. In addition, no significant difference was demonstrated between
the serum anti-rPA IgG GMT in any of the adjuvanted groups. Most notably, the powder
vaccine formulation stored for more than 2 years at room temperature was as effective as
any of the adjuvanted vaccines (liquid or powder) in eliciting systemic anti-PA IgG
response. It should be noted that rabbits were supine for 30s after vaccination with liquid
formulations in order to maximize its nasal residence time, while rabbits receiving powder
spray were immediately returned to their cages. The systemic IgG response may have been
much lower for nasal liquid groups if the rabbits were immediately returned to the upright
position following immunization due to liquid drainage 48.
Similar trends were seen in the day 56 ELISA results showing a continuous systemic
immune response with moderate increase in overall anti-PA IgG titer among all groups (in
the range of 1:106-1:108) (Figure 11-C). Additionally, the powder vaccine formulation
stored for more than 2 years at room temperature was as potent as any of the adjuvanted
vaccines and induced the highest serum anti-rPA IgG GMT of any of the nasal
immunization groups with a titer of 1:1.1 × 108.
Serum samples collected on day 35 and 56 were also tested for their ability to neutralize
anthrax lethal toxin (LeTx) using an in vivo macrophage toxicity assay. LeTx neutralization
titers are presented as the serum dilution required to neutralize 50% of the LeTx (NT50). At
day 35, all adjuvanted vaccine formulations, delivered IN or IM, had serum LeTx NT50
titers that were significantly greater than the LeTx NT50 in rabbits immunized IN with rPA
alone, which further demonstrates that C48/80 provided significant adjuvant activity (Figure
12-A). There were no significant differences in the LeTx NT50 between any of the
adjuvanted groups (nasal or IM delivery), although the LeTx NT50 induce by IM
immunization was the highest. It is important to point out that only 75% of the animals in
the nasal liquid rPA + C48/80 group had measurable LeTx NT50 while the two powder
groups and the IM group had measureable LeTx NT50 in all animals after only two
immunizations. Similar to ELISA results, the LeTx NT50 results demonstrates that powder
formulations induced serum antibody responses at a faster rate than the liquid IN formation
and similar to the IM rPA vaccine. As mentioned in the introduction, the serum toxin
neutralization ability in rabbits correlates very well to the protection against anthrax spore.
We believe the long-term storage stability of the powder vaccine formulation (at least 2
years room temp) and the ability of only 2 doses of powder vaccine to induce functional
toxin-neutralizing antibody responses makes this an ideal vaccine formulation for
biodefense applications offering the advantage of stockpiling and shipping of the vaccines in
the absence of a cold chain. Additionally, nasal vaccination with powder vaccne
formulations may provide a superior, needle-free vaccination regimen for the rapid
induction of protective immunity, in case of emergency.
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Anthrax LeTx neutralizing antibody responses of day 56 samples had a similar trend to day
35 samples, which demonostrates long term stability of dry powder vaccines. All adjuvanted
vaccine formulations, delivered IN or IM, had serum LeTx NT50 titers that were
significantly greater than the LeTx NT50 in rabbits immunized IN with rPA alone, once
again demonstrating that C48/80 provided significant adjuvant activity (Figure 12-B). There
were no significant differences in the LeTx NT50 between any of the adjuvanted groups
(nasal or IM delivery), although the LeTx NT50 induce by IM immunization was the highest.
By day 56, all rabbits vaccinated with an adjuvanted vaccine formulation (IN or IM) had
measurable anthrax toxin neutralizing antibody responses. The maximum serum LeTx NT50
was in the IM group (1:4,374) while the 2009 and 2007 powder nasal formulations had the
next highest LeTx NT50 (1:1,122 and 1:1,085, respectively). The serum LeTx NT50 in the
IN liquid rPA + C48/80 group was the lowest of the adjuvanted groups (1:607). It is
important to mention that others use much lower doses of rPA and rLF in their anthrax lethal
toxin neutralization (50 ng/ml rPA + 40 ng/ml rLF) 49 than our assay (187.5 ng/ml rPA +
187.5 ng/ml rLF) indicating that our calculated LeTx NT50 are likely under-estimates of the
toxin neutralization capacity of our vaccine-induced anti-serum.
These in-vivo results not only showed that the powder device efficiently delivered the
powders after two months of device storage time, but also confirmed results from in-vitro
stability study that rPA in a powder formulation was stable at room temperature upon 2.5
years of storage and C48/80 and was an effective mucosal adjuvant in the rabbit model. No
evident toxicity was observed for all the vaccine groups. All rabbits maintained continuous
weight gain throughout the study and all survived after the study.
CONCLUSION
SFD powders containing rPA and C48/80 were successfully prepared under controlled SFD
condition, with particle physicochemical properties appropriate for direct nasal application
to the rabbit nasal cavity. Formulation with protein and adjuvant did not change the particle
size distribution in comparison to SFD powders of pure trehalose. The spectral information
obtained from CD and FT-IR measurements demonstrated the rPA in SFD formulation
maintained their secondary structure after SFD process and storage. The retention of rPA
integrity was confirmed by results from SDS-PAGE and Native PAGE. The mast cell
degranulation assay and in-vitro macrophage toxicity assay were useful in determining the
functional stability of adjuvant and antigen rPA. The effectiveness of the SFD powder
formulation was further examined in-vivo in an animal study using Unitdose powder device
for nasal delivery in rabbits. Nasal delivery of SFD powder formulation of rPA and C48/80
either freshly prepared or stored for 2.5 years at room temperature was as effective as IM
injection of freshly prepared liquid formulation. This room temperature storage stability of
the SFD powder vaccine was achieved by storing the SFD vaccine formulation with
desiccant and packaging in a nasal delivery device to avoid moisture uptake.
Positive results from both in-vitro and in-vivo studies support the use of C48/80 as a new
class of adjuvant for mucosal vaccination. Direct nasal delivery of dry powder vaccine
formulation containing recombinant PA and an effective mucosal adjuvant may provide the
ultimate approach for developing a stable and effective alternative to improve current
available anthrax vaccines. In comparing with other complex vaccine delivery systems, the
simple dry powder approach seems far more likely to be clinically/commercially viable the
same required protection can be achieved.
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SEM images of SFD particles.
A) SFD trehalose low magnification, B) SFD trehalose high magnification, C) SFD
trehalose C48/80, D) SFD rPA formulation-1, E) SFD rPA formulation-2.
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Particle size distributions of SFD powder formulations.
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Particle size distributions of SFD powder formulations measured as powder spray from
Pfeiffer Unitdose device (PIA measurements) as determined by laser diffraction
measurement.
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Differential scanning calorimetry of SFD powders and pure C48/80.
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CD spectrum of rPA in Far-UV region.
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Second derivative FT-IR spectra of rPA in the Amide I region.
Top: unprocessed rPA control (0.25mg/ml), Bottom: rPA concentrated from reconstituted
SFD rPA formulation-2 (0.24mg/ml)
Note: secondary structure element was assigned according to Table 2 in Schüle et al Eur J
Pharm Biopharm. 2007, 65(1):1-9)
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SDS and Native PAGE of reconstituted rPA formulations.
LEFT: SDS-PAGE under reducing conditions. Lane 1, MW marker; Lane 2, SFDrPA
formulation-1 upon 1.5 year of storage; Lane 3, SFD rPA formulation22 freshly prepared;
Lane 4, rPA control; Lane 5, SFD C48/80 formulation freshly prepared.
RIGHT: Native-PAGE under non-reducing conditions. Lane 1, MW marker; Lane 2, SFD
rPA formulation-1 upon 1.5 year of storage; Lane 3, SFD rPA formulation-2 freshly
prepared; Lane 4, rPA control; Lane 5, SFD C48/80 formulation freshly prepared.
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Mast cell degranulation activity of SFD powder formulations. (Mean±SD, n=3).
Wang et al. Page 30














Antigen functional stability determined by macrophage toxicity assay.
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Powder Storage Stability Study.
A) SFD rPA powder storage stability at different temperature and relative humidity (%RH),
B) rPA liquid formulation stability at different temperature, C) powder liquid comparison at
25°C, D) powder liquid comparison at 40°C.
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Animal study serum ELISA results.
(A) day 7 seropositive results. (B) day 35 serum anti-rPA IgG GMT titers. (C) day 56 serum
anti-rPA IgG GMT titers. A one-way ANOVA followed by Tukey’s post test were
performed on log2 transformed ELISA titer. A statistical significance was revealed between
the adjuvanted groups and rPA alone group. (n=4, *, P < 0.05). Data are presented as ELISA
titers with geometric mean.
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Animal study serum lethal toxin neutralization results.
(A) day 35 serum LeTx NT50 titer. (B) day 56 serum LeTx NT50 titer.
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Table 1
Particle sizes of SFD formulations (Mean (SD), n=3).
Powders D90 (μm) D50 (μm) D10 (μm) Span
SFD Trehalose 69.32 (1.77) 27.48 (1.41) 5.50 (1.17) 2.32 (0.11)
SFD C48/80 Trehalose 37.09 (0.89) 20.15 (1.58) 4.45 (0.80) 1.62 (0.07)
SFD rPA formulation-1 72.95 (2.48) 28.32 (2.52) 10.92 (1.32) 2.19 (0.10)
SFD rPA formulation-2 50.13 (1.96) 24.37 (1.37) 8.28 (0.74) 1.72 (0.06)
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Table 2
SFD powder physical properties (Mean (SD), n=3).







SFD Trehalose 2.4 (0.16) 0.05 (0.02) 0.08 (0.03) 38.1 (3)
SFD C48/80
Trehalose 1.5 (0.14) 0.16 0.24 34.9
SFD rPA
formulation-1 5.2 (0.15) 0.12 0.18 37.8
SFD rPA
formulation-2 4.3 (0.17) 0.06 0.09 32.5
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Table 3
Powder delivery efficiency with Unitdose device +/− tips (Mean (SD), n=3).
SFD particles LD mode D50 (μm) Span
Emit Dose
%
Emitted Dose (w tip)
%
SFD Trehalose
PIL 27.48 (1.41) 2.32 (0.11) 99 (1.7) 100 (0)
Device PIA 37.3 (2.73) 2.14 (0.29)
SFD C48/80 Trehalose
PIL 20.15 (1.58) 1.62 (0.07) 99 (1) 99.7 (3.5)
Device PIA 29.4 (1.95) 2.1 (0.28)
SFD rPA formulation-2
PIL 24.37 (1.37) 1.72 (0.09) 99 (1.3) 98.5 (3.2)
Device PIA 33.9 (1.60) 2.52 (0.32)
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Table 4
Vaccine formulations prepared to test the potency of dry powder rPA vaccines.
Groups rPA Dose(μg) Route Adjuvant
1 liquid, rPA alone 30 Nasal NONE
2 liquid, rPA and C48/80 30 Nasal C48/80, 120 μg
3 Powder (prepared Aug.09) 30 Nasal C48/80, 120 μg
4 Powder (prepared Sep.07) 30 Nasal C48/80, 120 μg
5 liquid, IM 30 IM C48/80, 120 μg
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